TB Research

Fatal SARS-CoV-2 and <i>Mycobacterium tuberculosis</i> coinfection in an infant: insights from Botswana

Mulale UK, Kashamba T, Strysko J, Kyokunda LT

BMJ case reports · 2021-04

Abstract

We report a fatal case of SARS-CoV-2 and Mycobacterium tuberculosis coinfection in an infant, Botswana's first paediatric COVID-19-associated fatality. The patient, a 3-month-old HIV-unexposed boy, presented with fever and respiratory distress in the setting of failure to thrive. Both the patient and his mother tested positive for rifampin-sensitive M. tuberculosis (Xpert MTB/Rif) and SARS-CoV-2 (real time-PCR). Initially stable on supplemental oxygen and antitubercular therapy, the patient experienced precipitous clinical decline 5 days after presentation and subsequently died. Autopsy identified evidence of disseminated tuberculosis (TB) as well as histopathological findings similar to those described in recent reports of SARS-CoV-2 infections, including diffuse microthrombosis. TB remains a serious public health threat in hyperendemic regions like sub-Saharan Africa, and is often diagnosed late in infants. In addition to raising the question of additive/synergistic pathophysiology and/or immune reconstitution, this case of coinfection also highlights the importance of leveraging the COVID-19 pandemic response to strengthen efforts for TB prevention, screening and detection.

MeSH terms

  • Humans
  • Mycobacterium tuberculosis
  • Tuberculosis
  • Fatal Outcome
  • Infant
  • Botswana
  • Male
  • Coinfection
  • COVID-19